Loading clinical trials...

The Effect of Unfavorable Histological Features on the Oncological Outcomes of Colon Cancer | Clinical Trials | Clareo Health

UNKNOWN

The Effect of Unfavorable Histological Features on the Oncological Outcomes of Colon Cancer

NCT03794193•Peking Union Medical College Hospital

View on ClinicalTrials.gov

Summary

To explore the effect of unfavorable histological features on the clinical outcomes of patients receiving radical resection of colon cancer.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age: 18-100 years old;
•2. Postoperative pathology confirmed colon adenocarcinoma;
•3. The tumor is located from the cecum to the sigmoid colon;
•4. No distant organ metastasis;

Exclusion Criteria

•1. Simultaneous or metachronous multiple primary colorectal cancer;
•2. History of previous malignant tumors (except for completely cured cervical carcinoma in situ or basal cell carcinoma or squamous epithelial skin cancer)
•3. local excision procedure;
•4. palliative resection (R2 resection);
•5. pregnant or lactating women.

Key Dates

Start Date

January 1, 2016

Primary Completion Date

December 1, 2020

Completion Date

December 1, 2023

Last Updated

May 4, 2022

Enrollment

1,367

ESTIMATED participants

Conditions

Colon Cancer

Interventions

Radical resection of colon cancer

PROCEDURE

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGNA

Resilience and Equity in Aging, Cancer, and Health (REACH)

NCT04674267

Gastric CancerColon Cancer+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 4, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of Unfavorable Histological Features on the Oncological Outcomes of Colon Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Resilience and Equity in Aging, Cancer, and Health (REACH)

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Phase II Trial of Lung Chemoemobolization

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression